Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra Journal Article


Authors: Bretton, P. R.; Herr, H. W.; Whitmore, W. F. Jr; Badalament, R. A.; Kimmel, M.; Provet, J.; Oettgen, H. F.; Melamed, M. R.; Fair, W. R.
Article Title: Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra
Abstract: A total of 23 patients presenting with multifocal superficial bladder cancer and concomitant in situ transitional cell carcinoma of the prostatic urethra (mucosal in 19 and ductal in 4) underwent transurethral resection and intravesical bacillus Calmette-Guerin therapy. Median followup was 51.6 months (range 6 to 105 months). Of the 23 patients 13 (48 per cent) had a complete response with a median followup of 43.7 months without recurrence. Progression of some type (local, muscle invasion or metastasis) occurred in 10 patients (44 per cent); none occurred in the prostatic urethra. Median interval free of progression was 55.7 months; 7 of 10 patients required cystectomy for progression or refractory disease in the bladder (prostate negative for transitional cell carcinoma). A trial of complete transurethral resection plus intravesical bacillus Calmette-Guerin is a viable alternative to immediate radical cystectomy for patients with mucosal and/or ductal involvement of the prostatic urethra with in situ transitional cell carcinoma.
Keywords: clinical article; bcg vaccine; cystectomy; tumor growth; transurethral resection; bladder carcinoma; transitional cell carcinoma; topical drug administration; superficial cancer; human; priority journal; urethra prostatic part
Journal Title: Journal of Urology
Volume: 141
Issue: 4
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 1989-04-01
Start Page: 853
End Page: 855; discussion 855
Language: English
PUBMED: 2926879
PROVIDER: scopus
DOI: 10.1016/s0022-5347(17)41031-7
DOI/URL:
Notes: Article -- Export Date: 14 April 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Harry W Herr
    594 Herr
  2. Herbert F Oettgen
    130 Oettgen
  3. William R Fair
    342 Fair
  4. Willet F. Whitmore Jr
    139 Whitmore
  5. Myron Melamed
    148 Melamed
  6. Marek Kimmel
    46 Kimmel